






Review

The exercise IL-6 enigma in cancer

Samuel T. Orange ^{1,2,*,@} Jack Leslie ^{1,3,@} Mark Ross ^{4,@} Derek A. Mann ^{1,3,@} and Henning Wackerhage ^{5,@}

Interleukin (IL)-6 elicits both anticancer and procancer effects depending on the context, which we have termed the ‘exercise IL-6 enigma’. IL-6 is released from skeletal muscles during exercise to regulate short-term energy availability. Exercise-induced IL-6 provokes biological effects that may protect against cancer by improving insulin sensitivity, stimulating the production of anti-inflammatory cytokines, mobilising immune cells, and reducing DNA damage in early malignant cells. By contrast, IL-6 continuously produced by leukocytes in inflammatory sites drives tumorigenesis by promoting chronic inflammation and activating tumour-promoting signalling pathways. How can a molecule have such opposing effects on cancer? Here, we review the roles of IL-6 in chronic inflammation, tumorigenesis, and exercise-associated cancer prevention and define the factors that underpin the exercise IL-6 enigma.

Paradoxical role of IL-6 in cancer

Participating in 150–300 min per week of structured physical activity (i.e., exercise) reduces the risk of at least seven types of cancer: breast, colon, endometrial, kidney, and liver cancer, myeloma, and non-Hodgkin’s lymphoma [1]. The size of the relative risk reduction ranges from 10% to 27%, depending on the cancer site [1]. Exercise is associated with lower recurrence rates and improved survival in people diagnosed with colon, breast, and prostate cancers [2].

A breakthrough in the field will be to identify the exercise-induced bioactive material that underlies the association between exercise and cancer risk and survival. A notable candidate is the cytokine IL-6 [3]. IL-6 is released from contracting skeletal muscle during exercise to regulate short-term energy availability and is quickly eliminated from plasma upon exercise cessation [4]. Muscle-derived IL-6 enhances insulin sensitivity [5], stimulates the production of anti-inflammatory cytokines [6], reduces proliferation and DNA damage in cancer cells [7], and stimulates tumour infiltration of cytotoxic immune cells in mice [8]. Based on these findings, we propose that IL-6 plays a key role in the multiple health benefits of exercise, including protection against cancer.

A large body of evidence suggests that IL-6 promotes **tumorigenesis** [9] (see [Glossary](#)). IL-6 is secreted by leukocytes and **stromal cells** for up to 15 h at local inflammatory sites [10] and controls the switch from acute to chronic inflammation, which is linked to the development of many cancers [11]. IL-6 produced in the **tumour microenvironment (TME)** activates tumour-intrinsic signalling pathways and regulates the protumour behaviour of infiltrating stromal and immune cells [12].

We have termed the opposing effects of IL-6 in cancer the ‘exercise IL-6 enigma’. Here, we review the roles of IL-6 in chronic inflammation, tumorigenesis, and exercise-associated cancer prevention. We then define the factors that can explain the exercise IL-6 enigma and explore their mechanistic bases.

Highlights

Interleukin (IL)-6 can prevent or promote cancer development, depending on the context.

IL-6 is released from skeletal muscles during exercise.

IL-6 is also secreted by leukocytes and stromal cells at sites of inflammation and in the tumour microenvironment.

Muscle-derived IL-6 enhances insulin sensitivity in glycogen-storing tissues, stimulates the appearance of anti-inflammatory cytokines in the blood, mobilises cytotoxic immune cells, and reduces DNA damage in cancer cells. These biological effects may help protect against cancer formation and progression.

By contrast, sustained IL-6 signalling at sites of inflammation and in the tumour microenvironment promotes chronic low-grade inflammation and activates tumour-promoting signalling pathways.

¹Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK

²School of Biomedical, Nutritional and Sport Sciences, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK

³Newcastle Fibrosis Research Group, Bioscience Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK

⁴Institute of Life and Earth Sciences, School of Energy, Geoscience, Infrastructure and Society, Heriot-Watt University, Edinburgh, UK

⁵Department of Sport & Health Science, Technical University of Munich, Munich, Germany

IL-6 signalling

The IL-6 receptor complex consists of the IL-6 receptor α (IL-6R α) and **glycoprotein 130 (gp130)**. IL-6R α exists in a transmembrane and soluble form. **Classic signalling** is initiated when IL-6 binds to the membrane-bound form of IL-6R α (mbIL-6R α), forming a complex of IL-6 and mbIL-6R α . This complex then binds to two molecules of gp130, which triggers gp130 **dimerization** and formation of a complex consisting of IL-6, mbIL-6R α , and gp130. Classic signalling occurs in cell types that express mbIL-6R α , including skeletal muscle fibres, hepatocytes, and neutrophils [13]. Many cancer cell lines and human tumours have mbIL-6R α , although there is high variability in mRNA expression within and between cancer sites (Figure 1) [14,15].

IL-6 elicits biological effects on cell types that do not express mbIL-6R α by binding to the soluble form of IL-6R α (sIL-6R α) in extracellular fluids, such as in blood plasma [16]. The IL-6/sIL-6R α complex binds to gp130 on the plasma membrane of target cells, promoting gp130 dimerization.

*Correspondence:
sam.orange@newcastle.ac.uk
(S.T. Orange).
Twitter: @SamOrange01 (S.T. Orange),
@J__Leslie (J. Leslie), @DrMarkRoss
(M. Ross), @derekamann1 (D.A. Mann),
and @HeWaHippo (H. Wackerhage).




Figure 1. Interleukin-6 receptor (IL6R) expression in cancer cell lines and human tumours. Relative IL-6R mRNA expression data for (A) ~800 cancer cell lines across 14 cancer types retrieved from the Cancer Cell Line Encyclopedia (CCLC) [14] and (B) ~7000 human cancer samples across 14 cancer types retrieved from The Cancer Genome Atlas (TCGA) via cBioPortal [15].

This form of IL-6 signalling – known as **trans-signalling** – enables IL-6 signalling in diverse cell types because gp130 is expressed on the surface of most cells.

Two more IL-6 signalling modes have recently been identified: **trans-presentation** and **joint reconstituted signalling**. In trans-presentation, IL-6 binds to mbIL-6R α on a transmitting cell membrane and the IL-6/mbIL-6R α complex is presented to a receiving cell expressing gp130, triggering gp130 dimerization and downstream signalling in the receiving cell [17]. In joint reconstituted signalling, mbIL-6R α on **extracellular vesicles (EVs)** are transported and fused with cells that lack mbIL-6R α , enabling delayed classic signalling on cells that otherwise would only respond to trans-signalling or trans-presentation [18].

All IL-6 signalling modes activate the **JAK/STAT3 signalling pathway**. Formation of the entire IL-6 receptor complex (IL-6/IL-6R α /gp130) activates JAK and subsequently induces the phosphorylation of tyrosine residues within the cytoplasmic part of gp130. These phosphorylated tyrosine residues recruit a variety of molecules with **Src homology domain 2 (SH2 domain)** including STAT3, which is phosphorylated, dimerized, and consequently translocates to the nucleus to activate target genes including *c-myc*, *bcl2*, *cyclin D1*, and *MCP-1* [19]. gp130 phosphorylation also serves as a recruitment site for SH2-containing protein tyrosine phosphatase (SHP)-2, which promotes activation of PI3K/Akt and MAPK/ERK signalling [20].

IL-6, inflammation, and cancer

IL-6 in acute inflammation

Acute inflammation is a normal biological response to tissue damage and acts to restore tissue homeostasis. IL-6 is produced by macrophages, fibroblasts, and endothelial cells at sites of inflammation and controls the extent of tissue inflammatory responses. IL-6 induces the hepatic synthesis of **acute phase proteins** and stimulates the recruitment of neutrophils and lymphocytes to the inflammatory site by activating endothelial and smooth muscle cells to express **adhesion molecules** and release **chemokines** IL-8 and monocyte chemoattractant protein (MCP)-1 (also known as CCL2) [21,22]. Neutrophils and some lymphocyte subsets express mbIL-6R α and thus are responsive to IL-6 classic signalling. The mbIL-6R α can also be shed from neutrophil and lymphocyte membranes as a soluble form [23,24].

IL-6 in chronic inflammation

IL-6 trans-signalling in stromal cells induces a transition from neutrophilic recruitment in the early stages of acute inflammation to a more sustained monocyte influx by regulating a shift in chemokine production. The activation of neutrophils by IL-8 and other chemokines triggers mbIL-6R α shedding [25]. The sIL-6R α combines with IL-6 to enable binding to gp130 on the endothelial cell membrane, increasing IL-6 and MCP-1 secretion but not IL-8, which favours monocyte recruitment [26]. Monocytes differentiate into macrophages at the site of inflammation, which secrete proinflammatory cytokines [e.g., IL-1 β , tumour necrosis factor (TNF)- α , and IL-1]. Additionally, although the phagocytosis of apoptotic neutrophils by macrophages is important for the resolution of inflammation, this process increases MCP-1 and inhibits IL-8 production by macrophages [27,28], further favouring monocyte recruitment.

Chronic inflammation and cancer

Chronic inflammation associated with sustained IL-6 signalling can promote the transformation of normal cells into premalignant or malignant cells. Macrophages and neutrophils produce reactive oxygen species (ROS) that induce DNA damage in normal tissues, increasing genetic instability and the propensity of acquiring mutations in cancer-related genes. For instance, chronic exposure to myeloid cell-derived ROS molecules leads to DNA damage and *Tp53* mutations in

Glossary

Acute phase proteins: blood proteins produced by the liver in response to inflammation or infection, helping to stimulate the immune system and aid tissue repair. Examples of key acute phase proteins include C-reactive protein, serum amyloid A protein, and fibrinogen.

ADAM17: an enzyme involved in the shedding of membrane-bound proteins from cell surfaces, such as the IL-6 receptor, releasing their extracellular domains into the surrounding environment.

Adhesion molecules: cell surface proteins that mediate the interaction between cells, or between cells and the extracellular matrix. Adhesion molecules play a major role in the recruitment of neutrophils to the site of inflammation. An example of an adhesion molecule is the intercellular adhesion molecule 1 (ICAM-1).

Chemokines: small signalling proteins secreted by cells that control the movement of white blood cells to specific sites in the body, such as to sites of inflammation.

Classic signalling: mode of IL-6 signalling initiated when IL-6 binds to the membrane-bound IL-6 receptor on the surface of a cell.

Dedifferentiation: process by which specialised cells lose their specific characteristics and return to a less specialised state, often occurring during tissue repair and regeneration.

Dimerization: process of two molecules joining together to form a two-part complex (called a dimer). This often triggers downstream signal transduction.

Epithelial-mesenchymal transition (EMT): process in which epithelial cells lose their characteristic properties and acquire mesenchymal-like characteristics, leading to increased cell mobility and invasive capabilities, often associated with tissue development and cancer metastasis.

Extracellular vesicles (EVs): lipid-bound particles secreted by cells into the extracellular space. EVs carry a cargo of various molecules (e.g., proteins, lipids, and nucleic acids) and play a crucial role in cell-to-cell communication, allowing cells to exchange information and molecules with neighbouring or distant cells.

Glycoprotein 130 (gp130): cell surface receptor used by several cytokines to

inflamed intestinal epithelial cells [29]. Inflammatory signalling can also stimulate **dedifferentiation** of normal epithelial cells into tumour-initiating stem cells through a nuclear factor (NF)- κ B-dependent mechanism [30]. Moreover, prolonged IL-6 trans-signalling causes premature cellular senescence in fibroblasts [31] and promotes **senescence associated secretory phenotype (SASP)** signalling, which can drive epithelial plasticity and stemness [32], thus supporting the dedifferentiation and self-renewal of epithelial tissue.

Following the transformation of cells, inflammation-associated IL-6 may support progression into a fully developed tumour. IL-6 signalling in premalignant cells leads to the hyperactivation of JAK/STAT3 signalling, resulting in the upregulation of target genes that stimulate cell survival [33]. Persistent activation of STAT3 by IL-6 in tumour regulatory T cells helps transformed epithelium evade CD8⁺ T cell cytotoxicity [34]. IL-6 released by **myeloid-derived suppressor cells (MDSCs)** prevents functional differentiation of tumour-specific CD4⁺ T cells into effector T helper cells, leading to tumour progression in fibrosarcoma-bearing mice [35]. In slow proliferating tissues, such as liver and skin cells, necrosis and apoptosis caused by inflammation leads to compensatory proliferation of neighbouring transformed cells and triggers tumorigenesis [36].

IL-6 in the TME

The main sources of IL-6 in the TME are tumour cells, stromal cells and infiltrating immune cells, including fibroblasts, MDSCs, tumour-associated macrophages (TAMs), and CD4⁺ T cells [12]. mbIL-6R α is overexpressed in tumours compared to normal tissue [37–40] and cancer cells can shed mbIL-6R α from their cell surface, partly through the actions of **ADAM17** [41], and thus are responsive to both classic and trans IL-6 signalling. Chronic IL-6 signalling in the TME promotes tumour progression by activating tumour-intrinsic signalling pathways and eliciting protumour effects on infiltrating stromal cells. In contrast to chronic IL-6 signalling, acute activation of IL-6 in the TME may promote antitumour adaptive immunity by inducing the migration of cytotoxic T cells to tumour-draining lymph nodes and tumour vasculature (Figure 2).

Protumour mechanisms of IL-6 in the TME

Activation of STAT3 by IL-6 trans-signalling regulates gene expression resulting in cell cycle progression, proliferation, and survival [42]. Persistent IL-6/STAT3 signalling inactivates p53 in human multiple myeloma cells, in part by increasing the expression of DNA methyltransferase (DNMT)-1 [43], allowing cells to bypass crucial cell cycle checkpoints. Acting through STAT3, IL-6 upregulates vascular endothelial growth factor (VEGF) to promote angiogenesis in a range of solid tumours and primes cancer cells for metastatic spread by upregulating matrix metalloproteinase (MMP)-2 [44,45]. IL-6/STAT3 signalling also promotes **epithelial–mesenchymal transition (EMT)** by decreasing the expression of EMT-associated marker e-cadherin and increasing expression of vimentin [46]. IL-6 secreted by cancer-associated fibroblasts induces cancer stem cell expansion in early colorectal tumours through HES1 activation [47]. IL-6/STAT3 signalling promotes local immunosuppression via several mechanisms, including regulatory T cell and B cell expansion and recruiting immunosuppressive MDSC [48].

Antitumour mechanisms of IL-6 in the TME

There is some evidence that acute activation of IL-6 signalling promotes antitumour adaptive immunity by regulating T cell priming in lymphoid organs and stimulating lymphocyte trafficking [49]. IL-6 produced by dendritic cells in lymph nodes engenders the activation, expansion, and survival of T cells during an immune response [50]. IL-6 is important for the differentiation of naïve CD4⁺ T cells into Th17 cells and protects T cells from apoptosis [51]. IL-6 trans-signalling stimulates lymphocyte trafficking to tumour-draining lymph nodes by increasing intercellular adhesion molecule

trigger intracellular signalling. The binding of the IL-6/IL-6 receptor complex to gp130 forms a dimer and triggers downstream JAK/STAT3 signalling.

High endothelial venules: specialised blood vessels found in lymph nodes that facilitate the entry of immune cells from the blood to the lymphatic system.

JAK/STAT3 signalling pathway: important intracellular signalling cascade that is activated by various cytokines (including IL-6) and induces the transcription of target genes involved in cell cycle progression, proliferation, and survival.

Joint reconstituted signalling: process by which the membrane-bound IL-6 receptor on EVs is transported to, and fused with, cells that lack the IL-6 receptor on their surface. This process enables IL-6 classic signalling in cells that would otherwise only respond to trans-signalling or trans-presentation.

Myeloid-derived suppressor cells (MDSCs): diverse group of immune cells from the myeloid lineage that are able to suppress the activity of other immune cells, particularly T cells and natural killer cells. MDSC expand under pathological conditions such as chronic inflammation and cancer.

Senescence associated secretory phenotype (SASP): phenotype of senescent cells whereby those cells secrete high levels of proinflammatory cytokines and growth factors into their surrounding environment, which can reinforce the senescent state in neighbouring cells and promote chronic inflammation.

Src homology domain 2 (SH2 domain): region of a protein (called protein domain) that binds to specific phosphorylated tyrosine residues in other proteins, facilitating intracellular signalling. STAT3 contains the SH2 domain and it is essential for activating the JAK/STAT3 signalling pathway.

Stromal cells: diverse group of connective tissue cells of any organ, providing structural support and contributing to tissue organization, immune responses, and tissue repair. The most common type of stromal cells are fibroblasts, found abundantly in the connective tissues.

Trans-presentation: mode of IL-6 signalling in which IL-6 binds to the membrane-bound IL-6 receptor on a transmitting cell and subsequently engages and binds with gp130 on a neighbouring receiving cell.

(ICAM)-1 expression on **high endothelial venules**, which are the main entry site for naïve and central memory T cells [52].


Despite that IL-6 trans-signalling is constitutively active in pancreatic and colonic tumour types [52], vessels in these tumours typically express a low level of trafficking molecules (such as ICAM-1) and do not support the extravasation of circulating effector and naïve CD8⁺ T cells [52,53], suggesting that tumour endothelial cells are insensitive to chronic IL-6 activity. However, acute activation of IL-6 trans-signalling in murine models of colon and pancreatic cancer stimulates intratumoral CD8⁺ T cell infiltration by increasing tethering and rolling behaviour of CD8⁺ T cells and upregulating ICAM-1 density in tumour vessels [52]. Recombinant IL-6 also increases expression of ICAM-1 on intratumoral vessels in stage IV colorectal patient tumour explants, despite the presence of IL-6 in tumour lesions [52]. When combined with adoptive transfer of effector CD8⁺ T cells, acute IL-6 stimulation enhances apoptosis of tumour cells and delayed tumour growth [52].

Regular exercise reduces resting levels of intratumoral IL-6 in breast cancer-bearing mice, which correlates to reduced tumour size [54]. An acute bout of exercise induces the release of IL-6 into the systemic circulation [55], which may acutely activate IL-6 signalling in the TME because

Trans-signalling: mode of IL-6 signalling initiated when IL-6 binds to the soluble form of the IL-6 receptor in extracellular fluids, such as in blood plasma.

Tumorigenesis: formation of cancer, whereby normal cells are transformed into cancer cells.

Tumour microenvironment (TME): complex environment around a tumour, including the surrounding blood vessels, immune cells, stromal cells, signalling molecules and the extracellular matrix, all of which interact with the tumour and influence tumour growth and behaviour.



Trends in Endocrinology & Metabolism

Figure 2. Protumour and antitumour actions of IL-6 in the tumour microenvironment (TME). Persistent IL-6 signalling in the TME promotes all stages of tumorigenesis by supporting cell survival, angiogenesis, EMT, and metastatic spread through activation of the JAK/STAT3 pathway and regulation of tumour-infiltrating stromal and immune cells. Conversely, acute IL-6 signalling may promote antitumour adaptive immunity by regulating T cell priming in lymphoid organs and inducing the migration of cytotoxic T cells to tumour-draining lymph nodes and tumour vessels. Abbreviations: bFGF, basic fibroblast growth factor; EMT, epithelial-mesenchymal transition; HES1, transcription factor HES1; IL-6, interleukin-6; ICAM-1, intercellular adhesion molecule 1; MMP-2, matrix metalloproteinase-2; VEGF, vascular endothelial growth factor. Created with [BioRender.com](https://www.biorender.com).

plasma IL-6 is able to penetrate into the interstitial fluid bathing vascularised tumours [56]. Thus, exercise may shift the balance of IL-6 signalling in the TME away from chronic activation (protumour) and toward acute activation (antitumour).

Exercise, IL-6, and cancer protection

IL-6 response to acute exercise

IL-6 is released by skeletal muscle into the interstitium and systemic circulation during exercise and acts in autocrine/paracrine and endocrine fashions to shunt energy towards the contracting muscle [4]. Plasma IL-6 concentrations increase exponentially during a bout of exercise and reach their peak at exercise cessation [57]. Exercise bouts performed for longer durations, at higher intensities, and recruiting large muscle groups, result in the greatest increases in circulating IL-6 [55,58,59]. Muscle-derived IL-6 has a half-life of ~5 min and is quickly eliminated from plasma after exercise cessation due to increased hepatic clearance and cessation of skeletal muscle secretion [60,61].

An acute bout of exercise upregulates mbIL-6R α mRNA in skeletal muscle and there is evidence that myofibers do not shed mbIL-6R α [62]. Plasma levels of soluble gp130 (sgp130) increase following acute exercise [63,64]. sgp130 forms a ternary complex with IL-6/sIL-6R α in plasma to inhibit IL-6 trans-signalling [65]. Therefore, acute exercise may shift the IL-6 signalling axis away from trans-signalling and towards classic signalling.


Exercise-induced IL-6 in cancer prevention

Cancer prevention efforts can broadly be split into primary prevention (i.e., reducing the risk of developing cancer) and secondary or tertiary prevention (i.e., controlling the progression of precancerous or cancerous lesions).

IL-6 in primary cancer prevention

Putative biological mechanisms linking exercise to the primary prevention of site-specific cancers include improved insulin sensitivity, reduced bioavailability of exogenous sex hormones, and resolution of chronic low-grade inflammation [66]. Acute exercise has widespread effects on multiple organ systems and results in the rise and fall of thousands of bioactive molecules [67]. Therefore, many exercise-regulated biological processes are likely to impact on these pathways. As we describe below, there is good evidence that the biological actions of muscle-derived IL-6 directly or indirectly affect these pathways, and thus may play an important role in the exercise-associated prevention of cancer (Figure 3).

Evidence from *in vitro*, murine, and human studies suggests that IL-6 improves insulin resistance in glycogen-storing tissues. IL-6 infusion increases basal and insulin-stimulated glucose clearance in humans [5,68,69]. IL-6-deficient mice develop glucose intolerance, insulin resistance, and obesity [70–73], and the exercise-dependent increase in insulin sensitivity and GLUT4 expression is abolished by IL-6 knockout or IL-6 neutralizing antibodies [74,75]. IL-6 is required to elicit the exercise-dependent decrease in liver ectopic fat and browning of white adipose tissue *in vivo* [76,77]; both of which are characteristics of an insulin sensitive phenotype. Underlying these effects may be the IL-6-dependent upregulation of lipolytic and insulin-sensitizing genes, including peroxisome proliferator-activated receptor (PPAR)- γ and PPAR- γ coactivator (PGC)-1 α [76]. IL-6 increases insulin-stimulated glucose in skeletal muscle cells and adipocytes through AMPK activation [78,79], and improves glucose-stimulated insulin secretion in pancreatic beta cells [80]; likely by triggering GLP-1 secretion from intestinal L cells and pancreatic alpha cells, or enhancing insulin-degrading enzyme expression in skeletal muscle [72,81].



Trends in Endocrinology & Metabolism

Figure 3. Hypothesized biological mechanisms underlying the role of exercise-induced IL-6 in primary and secondary cancer prevention. *Metabolic effects.* IL-6 promotes GLUT4 translocation and glucose uptake in skeletal muscle, reduces visceral fat mass, increases lipolysis and glucose uptake in adipocytes, and stimulates GLP-1 secretion from intestinal L cells. *Anti-inflammatory effects.* IL-6 stimulates release of IL-10 and IL-1RA from macrophages and cortisol from adrenal glands, inhibits TNF α release from monocytes, reduces macrophage infiltration in adipose tissue, and promotes polarization of macrophages towards the anti-inflammatory M2 phenotype. *Immunoregulatory effects.* IL-6 contributes to the mobilisation of cytotoxic NK cells in humans and stimulates tumour infiltration of NK cells in mice, although exercise effects on NK cell tumour infiltration in humans is unclear. *Direct effects.* IL-6 directly inhibits cell proliferation and reduces DNA damage in early-stage colon cancer cells. Abbreviations: GLP-1, glucagon-like peptide 1; IGF, insulin-like growth factor 1; IGFBP-3, insulin-like growth factor binding protein 3; IL, interleukin; IL-1RA, IL-1 receptor antagonist; NK cell, natural killer cell; ROS, reactive oxygen species; SHBG, sex hormone binding globulin; TNF α , tumour necrosis factor α . Created with [BioRender.com](https://www.biorender.com).

However, some studies *in vitro* [82,83] and in mice [84,85] suggest that IL-6 causes insulin resistance, mainly in the liver. These opposing effects may depend on the duration of IL-6 exposure [86]. Chronic exposure to IL-6 for >24 h causes insulin resistance in adipose and hepatic tissue [87,88], whereas acute administration of IL-6 for \leq 60 min improves insulin sensitivity [78,89–91]. Time-course studies show that chronic (2–24 h) but not acute (30–60 min) exposure to IL-6 induces insulin resistance in adipocytes and hepatocytes [82,88].

Enhanced insulin sensitivity induced by IL-6 may lower cancer risk by increasing production of insulin-like growth factor binding protein (IGFBP)-3 and consequently reducing IGF-1 bioavailability [92]. Overstimulation of IGF-1 signalling is associated with an increased risk of several cancers, particularly breast, prostate, and colorectal cancers [93]. Improved insulin sensitivity also reduces the bioavailability of sex steroid hormones because insulin inhibits hepatic secretion of sex

hormone binding globulin (SHBG) and stimulates aromatase activity [94]. Exercise-induced reductions in the bioavailability of oestrogen and androgens protect against some hormone sensitive cancers, such as postmenopausal breast cancer [95].

In addition to improving insulin sensitivity, regular exercise may reduce cancer risk by resolving chronic low-grade inflammation. Each bout of exercise stimulates the induction of anti-inflammatory cytokines [96], and regular exercise leads to a reduction in visceral fat [97]; there is evidence that muscle-derived IL-6 mediates both of these mechanisms. IL-6 is required to elicit the exercise-dependent decrease in visceral fat in humans and mice [76,98]. Infusing physiological concentrations of IL-6 in humans mimics the anti-inflammatory effects of an exercise bout by inducing the appearance of anti-inflammatory cytokines IL-10 and IL-1 receptor antagonist (IL-1RA) into the circulation and suppressing production of the proinflammatory cytokine TNF- α [6,99]. IL-6 infusion also stimulates cortisol release into the circulation – a potent anti-inflammatory hormone – by acting directly on the adrenal medulla [100] and triggering release of adrenocorticotrophic hormone from the pituitary gland [101], replicating the impact of exercise on the hypothalamic–pituitary–adrenal axis. IL-6 promotes the polarization of macrophages towards the M2 (anti-inflammatory) phenotype rather than the M1 (proinflammatory) phenotype [102].

IL-6 in secondary/tertiary cancer prevention

The biological mechanisms underlying the effects of exercise on secondary/tertiary cancer prevention may occur through the same pathways as primary prevention, in addition to direct effects on cancer cells and modulation of the TME [103].

Growing evidence suggests that bioactive molecules released into the systemic circulation during exercise act directly on cancer cells to reduce proliferation [104]. Our meta-analysis showed that exposing breast, prostate, colon, and lung cancer cell lines to serum obtained immediately after an exercise bout reduces cell proliferation by ~9% compared to nonexercise serum [105]. Many of the bioactive molecules regulated by acute exercise have capacity to impact biological processes related to cell cycle progression and proliferation [106]. Given that the biological actions of IL-6 contribute to the maintenance of tissue homeostasis [107], IL-6 is a notable candidate. Indeed, our research and work by others show that directly stimulating cancer cells with IL-6 reduces cell growth or proliferation in colon, oestrogen-receptor-positive breast cancer, prostate, and meningioma cell lines [7, 108–110]. IL-6 reduces colon cancer cell proliferation in a dose–response manner up to 10 pg/ml [7], which is the typical postexercise plasma concentration found in human studies [55].

We have recently shown that exercise-induced IL-6 reduces colon cancer cell proliferation by regulating cellular DNA damage [7]. In line with findings from our meta-analysis [105], stimulating colon cancer cells with post-exercise serum reduced cell proliferation by 6% compared to nonexercise control serum [7]. This effect was accompanied by decreased expression of the DNA double-strand break marker γ -H2AX. Acute exercise also increased serum IL-6, and exposing colon cancer cells to recombinant IL-6 reduced cell proliferation and DNA damage in a dose-dependent manner, mimicking the effect of exercise [7]. These observations are consistent with evidence showing that IL-6 reduces DNA damage in cancer cells following exposure to DNA damaging agents [111], and activates DNA repair enzymes and improves liver repair after partial hepatectomy *in vivo* [112].

How might a reduction in DNA damage inhibit colon cancer cell proliferation? According to the oncogene-induced DNA damage model for cancer development, DNA damage (specifically DNA double-strand breaks) drives the early stages of carcinogenesis [113]. Aberrant cell

proliferation prompted by activated oncogenes induces DNA double strand breaks, and the sustained formation of DNA damage contributes to genomic instability, which is a hallmark of cancer cells and increases the propensity of acquiring additional genetic mutations favouring cancer progression [114]. Therefore, given that cancer cell lines are known to rapidly attain new genetic variants in culture, which accelerate proliferation [115], the IL-6-dependent reduction in DNA damage may inhibit cancer cell proliferation by shifting the cells towards a more genetically stable phenotype, reducing the acquisition of further genetic mutations [3].

There is evidence that IL-6 partially controls the innate immune response to acute exercise, which may inhibit cancer progression through the recognition and elimination of cancer cells [116]. A single bout of exercise mobilises CD8⁺ cytotoxic T cells and natural killer (NK) cells into the circulation in patients with prostate cancer and lymphoma [117,118]. Although β -adrenergic signalling and vascular wall shear stress are key to NK cell mobilisation, blocking IL-6 signalling (using tocilizumab) attenuated the increase in circulating NK cells by 53% and dendritic cells by 66% during an acute bout of exercise in humans [119]. Exercise selectively mobilises mIL-6R α -positive NK cells in mice [8] and treatment of NK cells with IL-6 increases their surface expression of adhesion molecules [120].

Voluntary wheel running in mice has been shown to increase the infiltration of cytotoxic NK cells in tumours, resulting in a 60% reduction in tumour growth across five different tumour models [8]. IL-6-blocking antibodies decreased the number of NK cells in the tumour and blunted the tumour-suppressive effect of wheel running, suggesting that exercise-induced IL-6 mediated these anticancer effects [8]. However, human studies have shown little evidence of an effect of exercise on NK tumour infiltration [121,122].

Factors that explain the exercise IL-6 enigma

As we have described, IL-6 acutely released from contracting skeletal muscle during exercise elicits different biological effects to IL-6 released for sustained periods at inflammatory sites. Below, we present five factors that can explain the exercise IL-6 enigma in cancer and draw on evidence to explore their mechanistic bases.

Duration of IL-6 exposure

Muscle-derived IL-6 is quickly eliminated from plasma upon exercise cessation with a half-life of ~5 min [60], whereas the half-life of IL-6 produced during acute inflammation is ~15 h [10,123] and plasma IL-6 is chronically elevated in people with cancer [124]. Acute IL-6 signalling induces biological responses that intercept carcinogenesis, whereas persistent IL-6 signalling predisposes tissues to cancer development. For instance, acute IL-6 signalling during exercise inducts an anti-inflammatory environment and enhances insulin sensitivity in glycogen-storing tissues, whereas sustained IL-6 signalling promotes chronic inflammation and insulin resistance. Short-term IL-6 administration improves liver regeneration and repair following partial hepatectomy, but chronic exposure sensitizes the liver to injury and death [125]. Directly exposing prostate cancer cells to IL-6 inhibits cell growth in the short term (<28 passages), but increases growth in the longer term (>42 passages) [109]. Further research is needed to understand the molecular mechanisms underlying the transition of IL-6 from an anticancer to pro-cancer agent as the duration of exposure increases.

In the TME, continuous IL-6 production is needed to support tumorigenesis in several tumour models. IL-6 facilitates epigenetic gene silencing of p53 in the IL-6-dependent myeloma cell line KAS 6/1 by increasing the activity of DNMT-1, but IL-6 only begins to inhibit p53 expression after 4 days of exposure [43]. Additionally, depriving KAS 6/1 cells of IL-6 results in continued p53

expression and cell death [43], suggesting that persistent IL-6 signalling is required to maintain enhanced expression of DNMT-1 and epigenetic gene silencing of p53. Despite chronically elevated IL-6 signalling in pancreatic and colonic TMEs [52], the tumour vessels express a low expression of adhesion molecules and CD8⁺ T cells are poorly represented, yet acute activation of IL-6 trans-signalling increases ICAM-1 density in tumour vessels and intratumoral infiltration of CD8⁺ T cells [52].

IL-6 signalling mode

IL-6 classic signalling is generally considered anti-inflammatory and IL-6 trans-signalling is considered proinflammatory, although the underlying mechanisms have remained elusive. IL-6 trans-signalling induces a stronger phosphorylation of STAT3 than classic signalling in endothelial cells and cancer cells [41,126]. When human vascular endothelial cells are exposed to IL-6 and sIL-6R α together, low concentrations of IL-6 are required to evoke STAT3 phosphorylation (1 ng/ml), whereas higher concentrations of IL-6 (50 ng/ml) are needed to induce a similar degree of STAT3 phosphorylation when sIL-6R α is not present [126]. Moreover, trans-signalling, but not classic signalling, leads to activation of the PI3K/Akt and MAPK/ERK signalling pathways in endothelial cells [126]. Simultaneous activation of the JAK/STAT3 and PI3K/Akt pathways is required to induce an IL-6-mediated proinflammatory response, characterised by the expression and release of MCP-1 [126]. Thus, concurrent JAK/STAT3, PI3K/Akt, and MAPK/ERK pathway activation, MCP-1 induction, and stronger STAT3 signalling seems to explain why trans-signalling is proinflammatory and classic signalling is anti-inflammatory. These differences may also explain why IL-6 exposure increases proliferation in oestrogen-receptor-negative breast cancer cells that do not express mbIL-6R α (i.e., acting via trans-signalling), but has growth-inhibitory effects on oestrogen-receptor-positive breast cancer cells that have mbIL-6R α (acting via classic signalling) [127].

IL-6 trans-signalling dominates in the TME; cancer cells shed mbIL-6R α from their cell surface and thus, in some cases, respond to trans but not classic IL-6 signalling [41]. T cells lose mbIL-6R α expression in inflamed microenvironments [128] and TAMs shed mbIL-6R α in the presence of ADAM17, which drives tumorigenesis [129,130]. IL-6 trans-signalling, but not classic signalling, decreases expression of tumour suppression gene maspin in prostate cancer cells [131].

It is not known whether exercise impacts the balance of trans- to classic signalling in the TME by, for example, increasing the ratio of mbIL-6R α to gp130 on the tumour membrane. The recent discovery of joint reconstituted signalling – involving mbIL-6R α on EVs fusing with cells that lack mbIL-6R α – opens up the possibility that cells could respond to IL-6 classic signalling without actually expressing the surface receptor [18]. This is especially important in the context of exercise given that EVs are liberated during acute exercise and carry protein cargo to distant organs [132].

Upstream regulation of IL-6

Signals of energetic stress during strenuous exercise, such as accumulation of Ca²⁺, lactate, and ROS, and activation of AMPK and p38 MAPK [133–136], stimulate the secretion of IL-6 from skeletal muscle, which occurs in the absence of NF- κ B signalling and TNF- α /IL-1 β secretion [137,138], and in the presence of anti-inflammatory cytokines IL-10 and IL-1RA [6]. By contrast, IL-6 released from inflammatory cells such as macrophages, stromal cells, and cancer cells largely depends on upstream NF- κ B signalling and occurs concurrently with TNF- α production [139]. Thus, when IL-6 release is triggered by upstream inflammatory signalling, IL-6 signalling occurs in microenvironments rich in DNA-damaging agents, genetic instability, growth factors, and activated stroma. IL-6/STAT3 signalling alone does not cause cancer, but persistent activation of

STAT3 in a milieu of inflammation and DNA damage can promote malignant transformation and progression [140].

Cell source of IL-6

The source of IL-6 influences its biological actions. Adipocyte-derived IL-6 promotes macrophage infiltration in mouse adipose tissue, but IL-6 released from skeletal muscles during exercise suppresses adipose tissue macrophage infiltration [141]. Others have shown that adipocyte-derived IL-6 decreases hepatic expression of the adapter protein IRS1 [142], while IL-6 derived from Kupffer cells (liver resident macrophages) increases the expression of the adapter protein IRS2 [143]. The underlying mechanisms are unresolved, but may be related to a switch between IL-6 classic- and trans-signalling due to differences in the expression of ADAM10/17 that

Key figure

The exercise IL-6 enigma in cancer




Figure 4. Signals of energetic stress during strenuous exercise induce the acute release of IL-6 from skeletal muscle to regulate energy availability. Acting via IL-6 classic-signalling, muscle-derived IL-6 may elicit antitumour effects by stimulating lipolysis in adipose tissue, increasing insulin sensitivity in glycogen storing tissues such as skeletal muscle, triggering the release of anti-inflammatory cytokines from monocytes and macrophages, mobilising cytotoxic immune cells, regulating DNA damage in malignant cells, and reducing cancer cell proliferation. By contrast, inflammatory signalling induces the prolonged release of IL-6 from macrophages, fibroblasts, and endothelial cells. IL-6 continuously secreted by inflammatory cells activates the trans-signalling pathway to elicit protumour effects by promoting insulin resistance in hepatocytes, inducing sustained monocyte recruitment to local inflammatory sites to control the switch from acute to chronic inflammation, provoking senescence and a senescence-associated secretory phenotype in stromal cells, stimulating proliferation, p53 inactivation, and metastatic potential in malignant cells, and supporting an immunosuppressive TME. Abbreviations: IL-6, interleukin-6; NF-κB, nuclear factor κB; ROS, reactive oxygen species; TME- tumour microenvironment; TNF-α, tumour necrosis factor-α. Created with [BioRender.com](https://www.biorender.com).

promotes mbIL-6R α shedding [141]. Unlike leukocytes and cancer cells, there is evidence that skeletal muscle cells do not shed mbIL-6R α [62]. It is hence biologically plausible that muscle-derived IL-6 acts partially through IL-6 classic signalling to elicit anticancer effects in tissues (e.g., increased insulin resistance, reduced chronic inflammation), while IL-6 released from tumour cells, fibroblasts, and TAMs in the TME acts through IL-6 trans-signalling to promote tumorigenesis.

Cell targeted by IL-6

Cells respond differently to IL-6; this is partly determined by the ratio of mbIL-6R α to gp130 on the cell surface and thus the balance of classic versus trans-signalling [144]. However, other cell-intrinsic factors are likely to be relevant, such as the expression of suppressor of cytokine signalling (SOCS)3, the primary negative regulator of IL-6 signalling. IL-6 inhibits the growth of M1 leukaemia cells, which completely lack expression of SOCS3 [145]. In addition, IL-6 induces an anti-inflammatory response in macrophages lacking the SOCS3 gene [146]. Site-specific cancer cells also respond differently to autocrine IL-6 stimulation; IL-6 is an autocrine growth stimulator in prostate cancer cells [109,147], whereas autocrine production of IL-6 inhibits proliferation in oestrogen-receptor-negative breast cancer cells [148].

Concluding remarks

Exercise scientists typically see IL-6 as a cytokine that prevents disease, whereas cancer researchers generally consider IL-6 to drive tumorigenesis. The evidence suggests both disciplines are correct because the biological effects of IL-6 are context dependent. IL-6 acutely released from skeletal muscle during exercise coordinates short-term energy allocation via IL-6 classic signalling and elicits biological effects that may contribute to cancer prevention, including increasing insulin sensitivity, inducing an anti-inflammatory environment, and reducing DNA damage. By contrast, chronically elevated IL-6 trans-signalling due to continuous release of IL-6 by stromal cells and macrophages promotes chronic inflammation and cancer formation (Figure 4, Key figure). The context-specific effects of IL-6 may explain why Phase 1/2 trials have reported limited clinical efficacy for the anti-IL-6 antibody siltuximab in patients with advanced solid tumours [149]. Factors that explain the paradoxical effects of IL-6 in cancer include the duration of IL-6 exposure, signalling mode, upstream regulation, cell source, and target cell. Future work should aim to better understand the mechanistic basis for these moderating factors. Doing so will help define the role of IL-6 in cancer and ultimately guide the development of more precise IL-6 therapies, through behavioural and pharmacological approaches, targeted to moderators and their underlying mechanistic pathways (see Outstanding questions).

Declaration of interests

No interests are declared.

References

1. Matthews, C.E. *et al.* (2019) Amount and intensity of leisure-time physical activity and lower cancer risk. *J. Clin. Oncol.* 38, 686–697
2. Cormie, P. *et al.* (2017) The impact of exercise on cancer mortality, recurrence, and treatment-related adverse effects. *Epidemiol. Rev.* 39, 71–92
3. Orange, S.T. (2023) What is the optimal type and dose of physical activity for colorectal cancer prevention? *Best Pract. Res. Clin. Gastroenterol.* Published online May 24, 2023. <https://doi.org/10.1016/j.bpg.2023.101841>
4. Kistner, T.M. *et al.* (2022) Interleukin 6 as an energy allocator in muscle tissue. *Nat. Metab.* 4, 170–179
5. Febbraio, M.A. *et al.* (2004) Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. *Diabetes* 53, 1643–1648
6. Steensberg, A. *et al.* (2003) IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. *Am. J. Physiol. Endocrinol. Metab.* 285, E433–E437
7. Orange, S.T. *et al.* (2022) Acute aerobic exercise-conditioned serum reduces colon cancer cell proliferation *in vitro* through interleukin-6-induced regulation of DNA damage. *Int. J. Cancer* 151, 265–274
8. Pedersen, L. *et al.* (2016) Voluntary running suppresses tumor growth through epinephrine- and IL-6-dependent NK cell mobilization and redistribution. *Cell Metab.* 23, 554–562
9. Johnson, D.E. *et al.* (2018) Targeting the IL-6/JAK/STAT3 signalling axis in cancer. *Nat. Rev. Clin. Oncol.* 15, 234–248
10. Kuribayashi, T. (2018) Elimination half-lives of interleukin-6 and cytokine-induced neutrophil chemoattractant-1 synthesized in

Outstanding questions

Several factors can explain the context-dependent effects of IL-6 in cancer, including the duration of IL-6 exposure, signalling mode, upstream regulation, cell source, and cell target. What are the precise mechanisms of action underlying these factors? Can the underlying pathways be precisely targeted through behavioural, pharmacological, or immunological approaches to improve cancer control outcomes?

Exercise-induced IL-6 reduces DNA damage and proliferation in cancer cell lines and stimulates the tumour infiltration of cytotoxic immune cells in mice. Can these findings be replicated in humans and, if so, do they translate into improved patient outcomes?

Does maximising the amount of IL-6 released during acute exercise through manipulation of exercise characteristics (type, duration, and intensity) optimise the protective effect of exercise on cancer? If so, is this a casual effect or does the amount of IL-6 released during exercise simply reflect the overall exercise dose?

What effect does exercise have on IL-6 signalling in the tumour microenvironment? For example, does exercise modify mbIL-6R α or SOCS3 expression in tumours?

Do tumour subtypes respond differently to exercise-induced IL-6 signalling?

- response to inflammatory stimulation in rats. *Lab. Anim. Res.* 34, 80–83
11. Thorssson, V. *et al.* (2018) The immune landscape of cancer. *Immunity* 48, 812–830.e14
 12. Fisher, D.T. *et al.* (2014) The two faces of IL-6 in the tumor microenvironment. *Semin. Immunol.* 26, 38–47
 13. Scheller, J. *et al.* (2011) The pro- and anti-inflammatory properties of the cytokine interleukin-6. *Biochim. Biophys. Acta* 1813, 878–888
 14. Ghandi, M. *et al.* (2019) Next-generation characterization of the Cancer Cell Line Encyclopedia. *Nature* 569, 503–508
 15. Whetzel, P.L. *et al.* (2011) BioPortal: enhanced functionality via new Web services from the National Center for Biomedical Ontology to access and use ontologies in software applications. *Nucleic Acids Res.* 39, W541–W545
 16. Wolf, J. *et al.* (2016) Different soluble forms of the interleukin-6 family signal transducer gp130 fine-tune the blockade of interleukin-6 trans-signaling. *J. Biol. Chem.* 291, 16186–16196
 17. Heink, S. *et al.* (2017) Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells. *Nat. Immunol.* 18, 74–85
 18. Arnold, P. *et al.* (2020) Joint reconstituted signaling of the IL-6 receptor via extracellular vesicles. *Cells* 9, 1307
 19. Heinrich, P.C. *et al.* (1998) Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. *Biochem. J.* 334, 297–314
 20. Eulenfeld, R. *et al.* (2012) Interleukin-6 signalling: more than Jaks and STATs. *Eur. J. Cell Biol.* 91, 486–495
 21. Gabay, C. (2006) Interleukin-6 and chronic inflammation. *Arthritis Res. Ther.* 8, S3
 22. Watson, C. *et al.* (1996) IL-6 acts on endothelial cells to preferentially increase their adherence for lymphocytes. *Clin. Exp. Immunol.* 105, 112–119
 23. Romano, M. *et al.* (1997) Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. *Immunity* 6, 315–325
 24. Briso, E.M. *et al.* (2008) Soluble IL-6R is produced by IL-6R ectodomain shedding in activated CD4 T cells. *J. Immunol. Baltim. Md. 1950* 180, 7102–7106
 25. Hurst, S.M. *et al.* (2001) IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. *Immunity* 14, 705–714
 26. Kaplanski, G. *et al.* (2003) IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. *Trends Immunol.* 24, 25–29
 27. Lee, S.-A. *et al.* (2021) Phagocyte chemoattraction is induced through the Mcp-1–Ccr2 axis during efferocytosis. *Cells* 10, 3115
 28. Fadok, V.A. *et al.* (1998) Macrophages that have ingested apoptotic cells *in vitro* inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF- β , PGE₂, and PAF. *J. Clin. Invest.* 101, 890–898
 29. Canli, Ö. *et al.* (2017) Myeloid cell-derived reactive oxygen species induce epithelial mutagenesis. *Cancer Cell* 32, 869–883.e5
 30. Schwitalla, S. *et al.* (2013) Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. *Cell* 152, 25–38
 31. Kojima, H. *et al.* (2012) The STAT3-IGFBP5 axis is critical for IL-6/gp130-induced premature senescence in human fibroblasts. *Cell Cycle Georget. Tex* 11, 730–739
 32. Ortiz-Montero, P. *et al.* (2017) Senescence-associated IL-6 and IL-8 cytokines induce a self- and cross-reinforced senescence/inflammatory milieu strengthening tumorigenic capabilities in the MCF-7 breast cancer cell line. *Cell Commun. Signal.* CCS 15, 17
 33. Grivennikov, S. *et al.* (2009) IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. *Cancer Cell* 15, 103–113
 34. Yu, H. *et al.* (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. *Nat. Rev. Cancer* 9, 798–809
 35. Tsukamoto, H. *et al.* (2013) Myeloid-derived suppressor cells attenuate TH1 development through IL-6 production to promote tumor progression. *Cancer Immunol. Res.* 1, 64–76
 36. Sakurai, T. *et al.* (2008) Hepatocyte necrosis induced by oxidative stress and IL-1 α release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. *Cancer Cell* 14, 156–165
 37. Simondurairaj, C. *et al.* (2019) Interleukin-6 receptor (IL-6R) expression in human gastric carcinoma and its clinical significance. *Cancer Investig.* 37, 293–298
 38. Nakamura, K. *et al.* (2020) Expression of interleukin-6 and the interleukin-6 receptor predicts the clinical outcomes of patients with soft tissue sarcomas. *Cancers* 12, 585
 39. Chen, Q. *et al.* (2017) High mRNA expression level of IL-6R was associated with better prognosis for patients with ovarian cancer: a pooled meta-analysis. *Sci. Rep.* 7, 8769
 40. Kim, S. *et al.* (2016) Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R *in vitro*. *Oncotarget* 7, 83148–83159
 41. Holmer, R. *et al.* (2015) Interleukin-6 trans-signaling increases the expression of carcinoembryonic antigen-related cell adhesion molecules 5 and 6 in colorectal cancer cells. *BMC Cancer* 15, 975
 42. Wei, L.-Y. *et al.* (2022) Effects of interleukin-6 on STAT3-regulated signaling in oral cancer and as a prognosticator of patient survival. *Oral Oncol.* 124, 105665
 43. Hodge, D.R. *et al.* (2005) Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. *Cancer Res.* 65, 4673–4682
 44. Zhang, N. *et al.* (2020) Activated STAT3 could reduce survival in patients with esophageal squamous cell carcinoma by up-regulating VEGF and cyclin D1 expression. *J. Cancer* 11, 1859–1868
 45. Xie, T.-X. *et al.* (2004) Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. *Oncogene* 23, 3550–3560
 46. Wang, L. *et al.* (2017) Cancer-associated fibroblasts enhance metastatic potential of lung cancer cells through IL-6/STAT3 signaling pathway. *Oncotarget* 8, 76116–76128
 47. Kim, B. *et al.* (2021) IL-6 and IL-8, secreted by myofibroblasts in the tumor microenvironment, activate HES1 to expand the cancer stem cell population in early colorectal tumor. *Mol. Carcinog.* 60, 188–200
 48. Zou, S. *et al.* (2020) Targeting STAT3 in cancer immunotherapy. *Mol. Cancer* 19, 145
 49. Chonov, D.C. *et al.* (2019) IL-6 activities in the tumour microenvironment. Part 1. *Open Access Maced. J. Med. Sci.* 7, 2391–2398
 50. Li, B. *et al.* (2018) IL-6 promotes T cell proliferation and expansion under inflammatory conditions in association with low-level ROR γ t expression. *J. Immunol. Baltim. Md. 1950* 201, 2934–2946
 51. Naugler, W.E. and Karin, M. (2008) The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. *Trends Mol. Med.* 14, 109–119
 52. Fisher, D.T. *et al.* (2011) IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. *J. Clin. Invest.* 121, 3846–3859
 53. Mikucki, M.E. *et al.* (2013) Preconditioning thermal therapy: flipping the switch on IL-6 for anti-tumour immunity. *Int. J. Hyperther. Off. J. Eur. Soc. Hyperthermic Oncol. North Am. Hyperther. Group* 29, 464–473
 54. Shalamzari, S.A. *et al.* (2014) The effect of exercise training on the level of tissue IL-6 and vascular endothelial growth factor in breast cancer bearing mice. *Iran. J. Basic Med. Sci.* 17, 231–258
 55. Fischer, C.P. (2006) Interleukin-6 in acute exercise and training: what is the biological relevance? *Exerc. Immunol. Rev.* 12, 6–33
 56. Wiig, H. and Swartz, M.A. (2012) Interstitial fluid and lymph formation and transport: physiological regulation and roles in inflammation and cancer. *Physiol. Rev.* 92, 1005–1060
 57. Ostrowski, K. *et al.* (1998) A trauma-like elevation of plasma cytokines in humans in response to treadmill running. *J. Physiol.* 513, 889–894
 58. Cullen, T. *et al.* (2016) Interleukin-6 and associated cytokine responses to an acute bout of high-intensity interval exercise: the effect of exercise intensity and volume. *Appl. Physiol. Nutr. Metab. Physiol. Appl. Nutr. Metab.* 41, 803–808
 59. Ostrowski, K. *et al.* (2000) Physical activity and plasma interleukin-6 in humans – effect of intensity of exercise. *Eur. J. Appl. Physiol.* 83, 512–515

60. Toff, A.D. *et al.* (2011) Source and kinetics of interleukin-6 in humans during exercise demonstrated by a minimally invasive model. *Eur. J. Appl. Physiol.* 111, 1351–1359
61. Febbraio, M.A. *et al.* (2003) Hepatosplanchnic clearance of interleukin-6 in humans during exercise. *Am. J. Physiol. Endocrinol. Metab.* 285, E397–E402
62. Keller, C. *et al.* (2005) Effect of exercise, training, and glycogen availability on IL-6 receptor expression in human skeletal muscle. *J. Appl. Physiol.* (1985) 99, 2075–2079
63. Gray, S.R. *et al.* (2008) Response of plasma IL-6 and its soluble receptors during submaximal exercise to fatigue in sedentary middle-aged men. *Cell Stress Chaperones* 13, 247–251
64. Walshe, I. *et al.* (2010) The reliability of the IL-6, sIL-6R and sgp130 response to a preloaded time trial. *Eur. J. Appl. Physiol.* 110, 619–625
65. Jostock, T. *et al.* (2001) Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. *Eur. J. Biochem.* 268, 160–167
66. Friedenreich, C.M. *et al.* (2021) Physical activity, obesity and sedentary behavior in cancer etiology: epidemiologic evidence and biologic mechanisms. *Mol. Oncol.* 15, 790–800
67. Contrepois, K. *et al.* (2020) Molecular choreography of acute exercise. *Cell* 181, 1112–1130.e16
68. Lang Lehrskov, L. *et al.* (2018) Interleukin-6 delays gastric emptying in humans with direct effects on glycemic control. *Cell Metab.* 27, 1201–1211.e3
69. Lyngso, D. *et al.* (2002) Metabolic effects of interleukin-6 in human splanchnic and adipose tissue. *J. Physiol.* 543, 379–386
70. Matthews, V.B. *et al.* (2010) Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance. *Diabetologia* 53, 2431–2441
71. Wallenius, V. *et al.* (2002) Interleukin-6-deficient mice develop mature-onset obesity. *Nat. Med.* 8, 75–79
72. Kurauti, M.A. *et al.* (2017) Interleukin-6 increases the expression and activity of insulin-degrading enzyme. *Sci. Rep.* 7, 46750
73. Wunderlich, F.T. *et al.* (2010) Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action. *Cell Metab.* 12, 237–249
74. Ikeda, S.-I. *et al.* (2016) Exercise-induced increase in IL-6 level enhances GLUT4 expression and insulin sensitivity in mouse skeletal muscle. *Biochem. Biophys. Res. Commun.* 473, 947–952
75. Benrick, A. *et al.* (2012) Interleukin-6 mediates exercise-induced increase in insulin sensitivity in mice. *Exp. Physiol.* 97, 1224–1235
76. Li, L. *et al.* (2021) Interleukin-6 mediated exercise-induced alleviation of adiposity and hepatic steatosis in mice. *BMJ Open Diabetes Res. Care* 9, e001431
77. Knudsen, J.G. *et al.* (2014) Role of IL-6 in exercise training- and cold-induced UCP1 expression in subcutaneous white adipose tissue. *PLoS One* 9, e84910
78. Carey, A.L. *et al.* (2006) Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation *in vitro* via AMP-activated protein kinase. *Diabetes* 55, 2688–2697
79. Stouthard, J.M. *et al.* (1996) Interleukin-6 enhances glucose transport in 3T3-L1 adipocytes. *Biochem. Biophys. Res. Commun.* 220, 241–245
80. Suzuki, T. *et al.* (2011) Interleukin-6 enhances glucose-stimulated insulin secretion from pancreatic beta-cells: potential involvement of the PLC-IP3-dependent pathway. *Diabetes* 60, 537–547
81. Ellingsgaard, H. *et al.* (2011) Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. *Nat. Med.* 17, 1481–1489
82. Senn, J.J. *et al.* (2002) Interleukin-6 induces cellular insulin resistance in hepatocytes. *Diabetes* 51, 3391–3399
83. Kim, J.-H. *et al.* (2008) Regulation of interleukin-6-induced hepatic insulin resistance by mammalian target of rapamycin through the STAT3-SOCS3 pathway. *J. Biol. Chem.* 283, 708–715
84. Franckhauser, S. *et al.* (2008) Overexpression of IL6 leads to hyperinsulinaemia, liver inflammation and reduced body weight in mice. *Diabetologia* 51, 1306–1316
85. Cai, D. *et al.* (2005) Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. *Nat. Med.* 11, 183–190
86. Carey, A.L. and Febbraio, M.A. (2004) Interleukin-6 and insulin sensitivity: friend or foe? *Diabetologia* 47, 1135–1142
87. Klover, P.J. *et al.* (2003) Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. *Diabetes* 52, 2784–2789
88. Rotter, V. *et al.* (2003) Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. *J. Biol. Chem.* 278, 45777–45784
89. Peppler, W.T. *et al.* (2019) Acute administration of IL-6 improves indices of hepatic glucose and insulin homeostasis in lean and obese mice. *Am. J. Physiol.-Gastrointest. Liver Physiol.* 316, G166–G178
90. Saini, A. *et al.* (2014) Interleukin-6 in combination with the interleukin-6 receptor stimulates glucose uptake in resting human skeletal muscle independently of insulin action. *Diabetes Obes. Metab.* 16, 931–936
91. Weigert, C. *et al.* (2006) Direct cross-talk of interleukin-6 and insulin signal transduction via insulin receptor substrate-1 in skeletal muscle cells. *J. Biol. Chem.* 281, 7060–7067
92. Sandhu, M.S. *et al.* (2002) Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. *JNCI J. Natl. Cancer Inst.* 94, 972–980
93. Avgerinos, K.I. *et al.* (2019) Obesity and cancer risk: emerging biological mechanisms and perspectives. *Metabolism.* 92, 121–135
94. Randolph, J.F. *et al.* (1987) The effect of insulin on aromatase activity in isolated human endometrial glands and stroma. *Am. J. Obstet. Gynecol.* 157, 1534–1539
95. Drummond, A.E. *et al.* (2022) Linking physical activity to breast cancer via sex steroid hormones, part 2: the effect of sex steroid hormones on breast cancer risk. *Cancer Epidemiol. Biomark. Prev.* 31, 28–37
96. Dantas, W.S. *et al.* (2019) Exercise-induced anti-inflammatory effects in overweight/obese women with polycystic ovary syndrome. *Cytokine* 120, 66–70
97. Recchia, F. *et al.* (2023) Dose–response effects of exercise and caloric restriction on visceral adiposity in overweight and obese adults: a systematic review and meta-analysis of randomised controlled trials. *Br. J. Sports Med.* 57, 1035–1041
98. Wedell-Neergaard, A.-S. *et al.* (2019) Exercise-induced changes in visceral adipose tissue mass are regulated by IL-6 signaling: a randomized controlled trial. *Cell Metab.* 29, 844–855.e3
99. Starkie, R. *et al.* (2003) Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. *FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol.* 17, 884–886
100. Jenkins, D.E. *et al.* (2016) Interleukin-6-mediated signaling in adrenal medullary chromaffin cells. *J. Neurochem.* 139, 1138–1150
101. Späth-Schwalbe, E. *et al.* (1994) Interleukin-6 stimulates the hypothalamus-pituitary-adrenocortical axis in man. *J. Clin. Endocrinol. Metab.* 79, 1212–1214
102. Chen, L. *et al.* (2018) IL-6 influences the polarization of macrophages and the formation and growth of colorectal tumor. *Oncotarget* 9, 17443–17454
103. Brown, J.C. and Gilmore, L.A. (2020) Physical activity reduces the risk of recurrence and mortality in cancer patients. *Exerc. Sport Sci. Rev.* 48, 67
104. Metcalfe, R.S. *et al.* (2021) Anti-carcinogenic effects of exercise-conditioned human serum: evidence, relevance and opportunities. *Eur. J. Appl. Physiol.* 121, 2107–2124
105. Orange, S.T. *et al.* (2020) The serological responses to acute exercise in humans reduce cancer cell growth *in vitro*: a systematic review and meta-analysis. *Physiol. Rep.* 8, e14635
106. Severinsen, M.C.K. and Pedersen, B.K. (2020) Muscle–organ crosstalk: the emerging roles of myokines. *Endocr. Rev.* 41, 594
107. Jenkins, R.H. *et al.* (2021) Unravelling the broader complexity of IL-6 involvement in health and disease. *Cytokine* 148, 155684
108. Celik, A. and Bakar-Ates, F. (2021) The confounding effect of interleukin-6 on apoptosis of MCF-7 cells through down-

- regulation of MMP-2/-9 mRNA expression. *Turk. J. Biochem.* 46, 549–555
109. Lee, S.O. *et al.* (2007) Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. *Prostate* 67, 764–773
 110. Todo, T. *et al.* (1994) Secretion of interleukin-6 by human meningioma cells: possible autocrine inhibitory regulation of neoplastic cell growth. *J. Neurosurg.* 81, 394–401
 111. Matsuo, Y. *et al.* (2016) IL-6 controls resistance to radiation by suppressing oxidative stress via the Nrf2-antioxidant pathway in oral squamous cell carcinoma. *Br. J. Cancer* 115, 1234–1244
 112. Tachibana, S. *et al.* (2014) Interleukin-6 is required for cell cycle arrest and activation of DNA repair enzymes after partial hepatectomy in mice. *Cell Biosci.* 4, 6
 113. Halazonetis, T.D. *et al.* (2008) An oncogene-induced DNA damage model for cancer development. *Science* 319, 1352–1355
 114. Negrini, S. *et al.* (2010) Genomic instability — an evolving hallmark of cancer. *Nat. Rev. Mol. Cell Biol.* 11, 220–228
 115. Ben-David, U. *et al.* (2018) Genetic and transcriptional evolution alters cancer cell line drug response. *Nature* 560, 325–330
 116. Idorn, M. and Hojman, P. (2016) Exercise-dependent regulation of NK cells in cancer protection. *Trends Mol. Med.* 22, 565–577
 117. Schauer, T. *et al.* (2022) The effects of acute exercise and inflammation on immune function in early-stage prostate cancer. *Brain Behav. Immun. - Health* 25, 100508
 118. Koivula, T. *et al.* (2023) Acute exercise mobilizes CD8+ cytotoxic T cells and NK cells in lymphoma patients. *Front. Physiol.* 13, 1078512
 119. Bay, M.L. *et al.* (2020) Human immune cell mobilization during exercise: effect of IL-6 receptor blockade. *Exp. Physiol.* 105, 2086–2098
 120. Rabinowich, H. *et al.* (1993) Response of human NK cells to IL-6 alterations of the cell surface phenotype, adhesion to fibronectin and laminin, and tumor necrosis factor- α /beta secretion. *J. Immunol. Baltim. Md.* 1950 150, 4844–4855
 121. Djurhuus, S.S. *et al.* (2023) Exercise training to increase tumour natural killer-cell infiltration in men with localised prostate cancer: a randomised controlled trial. *BJU Int.* 131, 116–124
 122. Schenk, A. *et al.* (2022) Distinct distribution patterns of exercise-induced natural killer cell mobilization into the circulation and tumor tissue of patients with prostate cancer. *Am. J. Physiol. Cell Physiol.* 323, C879–C884
 123. Wirtz, D.C. *et al.* (2000) Interleukin-6: a potential inflammatory marker after total joint replacement. *Int. Orthop.* 24, 194–196
 124. Lippitz, B.E. (2013) Cytokine patterns in patients with cancer: a systematic review. *Lancet Oncol.* 14, e218–e228
 125. Jin, X. *et al.* (2006) Paradoxical effects of short- and long-term interleukin-6 exposure on liver injury and repair. *Hepatology* 43, 474–484
 126. Zegeye, M.M. *et al.* (2018) Activation of the JAK/STAT3 and PI3K/AKT pathways are crucial for IL-6 trans-signaling-mediated pro-inflammatory response in human vascular endothelial cells. *Cell Commun. Signal.* 16, 55
 127. Dethlefsen, C. *et al.* (2013) The role of intratumoral and systemic IL-6 in breast cancer. *Breast Cancer Res. Treat.* 138, 657–664
 128. Jones, G.W. *et al.* (2010) Loss of CD4+ T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells. *J. Immunol. Baltim. Md.* 1950 184, 2130–2139
 129. Schumacher, N. *et al.* (2015) Shedding of endogenous interleukin-6 receptor (IL-6R) is governed by a disintegrin and metalloproteinase (ADAM) proteases while a full-length IL-6R isoform localizes to circulating microvesicles. *J. Biol. Chem.* 290, 26059–26071
 130. S.P. Gnosa, *et al.*, ADAM17-mediated EGFR ligand shedding directs macrophage-promoted cancer cell invasion, *JCI Insight*, 7, e155296.
 131. Santer, F.R. *et al.* (2010) Interleukin-6 trans-signaling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells. *Endocr. Relat. Cancer* 17, 241–253
 132. Whitham, M. *et al.* (2018) Extracellular vesicles provide a means for tissue crosstalk during exercise. *Cell Metab.* 27, 237–251.e4
 133. Chan, M.H.S. *et al.* (2004) Altering dietary nutrient intake that reduces glycogen content leads to phosphorylation of nuclear p38 MAP kinase in human skeletal muscle: association with IL-6 gene transcription during contraction. *FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol.* 18, 1785–1787
 134. Hojman, P. *et al.* (2019) IL-6 release from muscles during exercise is stimulated by lactate-dependent protease activity. *Am. J. Physiol. Endocrinol. Metab.* 316, E940–E947
 135. Fischer, C.P. *et al.* (2004) Supplementation with vitamins C and E inhibits the release of interleukin-6 from contracting human skeletal muscle. *J. Physiol.* 558, 633–645
 136. Lauritzen, H.P.M.M. *et al.* (2013) Contraction and AICAR stimulate IL-6 vesicle depletion from skeletal muscle fibers *in vivo*. *Diabetes* 62, 3081–3092
 137. Steensberg, A. *et al.* (2007) Nitric oxide production is a proximal signaling event controlling exercise-induced mRNA expression in human skeletal muscle. *FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol.* 21, 2683–2694
 138. Petersen, A.M.W. and Pedersen, B.K. (2005) The anti-inflammatory effect of exercise. *J. Appl. Physiol. Bethesda Md* 1985 98, 1154–1162
 139. Liu, T. *et al.* (2017) NF- κ B signaling in inflammation. *Signal Transduct. Target. Ther.* 2, 17023
 140. Coussens, L.M. and Werb, Z. (2002) Inflammation and cancer. *Nature* 420, 860–867
 141. Han, M.S. *et al.* (2020) Regulation of adipose tissue inflammation by interleukin 6. *Proc. Natl. Acad. Sci. U. S. A.* 117, 2751–2760
 142. Sabio, G. *et al.* (2008) A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. *Science* 322, 1539–1543
 143. Awazawa, M. *et al.* (2011) Adiponectin enhances insulin sensitivity by increasing hepatic IRS-2 expression via a macrophage-derived IL-6-dependent pathway. *Cell Metab.* 13, 401–412
 144. Reeh, H. *et al.* (2019) Response to IL-6 trans- and IL-6 classic signalling is determined by the ratio of the IL-6 receptor α to gp130 expression: fusing experimental insights and dynamic modelling. *Cell Commun. Signal. CCS* 17, 46
 145. Suzuki, R. *et al.* (1998) CIS3 and JAB have different regulatory roles in interleukin-6 mediated differentiation and STAT3 activation in M1 leukemia cells. *Oncogene* 17, 2271–2278
 146. Yasukawa, H. *et al.* (2003) IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. *Nat. Immunol.* 4, 551–556
 147. Giri, D. *et al.* (2001) Interleukin-6 is an autocrine growth factor in human prostate cancer. *Am. J. Pathol.* 159, 2159–2165
 148. Selander, K.S. *et al.* (2004) Inhibition of gp130 signaling in breast cancer blocks constitutive activation of Stat3 and inhibits *in vivo* malignancy. *Cancer Res.* 64, 6924–6933
 149. Angevin, E. *et al.* (2014) A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors. *Clin. Cancer Res.* 20, 2192–2204